ArticleScientific reports2023
Exploring preferences and decision-making about long-acting injectable HIV pre-exposure prophylaxis (PrEP) among young sexual minority men 17-24 years old.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- PrEPSteps: A Pilot Randomized Controlled Trial to Assess the Feasibility and Acceptability of a Digital Pill-Based PrEP Adherence Intervention in Men Who Have Sex with Men with Substance Use Disorder.AIDS and behavior · 2026Trial
- Exploring the Interest and Intention to Use Long-Acting Injectable PrEP (LAI-PrEP) Among Gay, Bisexual and Other Men Who Have Sex with Men (GBMSM) in the Netherlands.AIDS and behavior · 2026Article
- PrEP uptake, persistence, and patterns of choice dynamics between oral and long-acting injectable with cabotegravir among sexually and gender-diverse adolescents in Brazil: a multisite cohort implementation study.Lancet regional health. Americas · 2026Article
- Trust and task-sharing: the acceptability of nurses and peer educators in PrEP delivery among sexually and gender-diverse adolescents in Brazil.Research square · 2026Article
- PrEP-Related Medical, Structural and Institutional Mistrust among a Socioeconomically Diverse Sample of Black, Latine, Asian, and White Young Sexual Minority Men: Lived Experiences of Intersectional Inequity.AIDS and behavior · 2026Article
- Utilisation of HIV pre-exposure prophylaxis and preferences of alternative long-acting modalities among men who have sex with men in Hong kong: a cross-sectional study.BMC public health · 2025Article
- Opinions and Concerns Surrounding Long-Acting Injectable (LAI) and Oral HIV Pre-exposure Prophylaxis (PrEP) Among Current and Former LAI and Oral PrEP Users.AIDS and behavior · 2025Article
- Inequities in PrEP annualized pill-day coverage, United States, 2018-2022: a cross-sectional pharmacoequity analysis.Journal of the International AIDS Society · 2025Article
- Pre-Exposure Prophylaxis Awareness and Demand Creation: Overlooked Populations and Opportunities to Move Forward.Journal of acquired immune deficiency syndromes (1999) · 2025Article
- Long-Acting Injectable Pre-Exposure Prophylaxis Perceptions and Preferences Among Transgender and Nonbinary Young Adults in the United States.Qualitative health research · 2025Article
- Hypothetical Preferences and Concerns for Long-Acting Injectable HIV PrEP Use Among Female Barmaids in Ubungo, Dar Es Salaam, Tanzania.HIV/AIDS (Auckland, N.Z.) · 2025Article
- Preferences for Starting Daily, On-Demand, and Long-Acting Injectable HIV Preexposure Prophylaxis Among Men Who Have Sex With Men in the United States (2021-2022): Nationwide Online Cross-Sectional Study.JMIR public health and surveillance · 2024Article
- Navigating Barriers and Opportunities: Perceptions of the Non-Occupational Post-Exposure Prophylaxis Care Continuum Among Young Sexual Minority Men, Aged 17-24, in the United States.AIDS patient care and STDs · 2024Article
- Need for informed providers: exploring LA-PrEP access in focus groups with PrEP-indicated communities in Baltimore, Maryland.BMC public health · 2024Article
- HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study.Journal of the International AIDS Society · 2024Article
- Willingness and preferences for long-acting injectable PrEP among US men who have sex with men: a discrete choice experiment.BMJ open · 2024Article
- High Propensity to Switch to Long-acting Injectable HIV PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men in Italy.AIDS and behavior · 2024Article
- Willingness to pay and price elasticity of demand for long-acting injectable cabotegravir among men who have sex with men in Guangxi, China.Frontiers in pharmacology · 2024Article
- Preferred Characteristics for mHealth Interventions Among Young Sexual Minoritized Men to Support HIV Testing and PrEP Decision-Making: Focus Group Study.JMIR formative research · 2023Article
- Variation in Preferences for Long-Acting Injectable Pre-Exposure Prophylaxis Among US Men Who Have Sex with Men: A Latent Class Analysis.AIDS patient care and STDs · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Intramuscular cabotegravir for long-acting injectable HIV pre-exposure prophylaxis (i.e., LAI-PrEP) was approved by the U.S. FDA in 2021. We sought to explore LAI-PrEP decision-making among a nationwide sample of young sexual minority men (YSMM) 17-24 years old. In 2020, HIV-negative/unknown YSMM (n = 41) who met CDC criteria for PrEP were recruited online to participate in synchronous online focus groups eliciting preferences and opinions about LAI-PrEP, as well as the impact of a potential self-administered option. Data were analyzed using inductive and deductive thematic analysis with constant comparison. Preferences and decision-making about LAI-PrEP varied widely among YSMM, with participants frequently comparing LAI-PrEP to oral PrEP regimens. We identified five key themes related to LAI-PrEP decision-making including concerns about adherence to PrEP dosing and clinic appointments, awareness and knowledge of PrEP safety and efficacy data, comfort with needles, minimizing PrEP stigma, and considerations of self-administration. YSMM acknowledged more PrEP options as beneficial to supporting uptake and persistence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.